Funding for clinical trials and/or clinical trial sub-studies with excellent preliminary data.
Eligibility: Principal applicants must be at or above the level of Assistant Professor or equivalent at a CRA qualified institution located in Canada. Project must involve the development of a therapeutic, and/or a tool to help accelerate the development of therapeutics for neurodegenerative diseases of aging.
NEW for 2018/2019:
Certain complementary approaches (i.e., diet, physical activity, sleep and nutritional supplements) will be eligible for funding through the Early Phase Clinical Trials program, if applications meet our disease and project scope criteria.
We encourage applications that bring in expertise, technologies or approaches in the following areas to advance the development of therapeutics and tools for neurodegenerative diseases of aging: Artificial Intelligence, big data, machine learning, data science, computer science, medicinal chemistry, biostatistics and engineering. Read more.